Publications by authors named "James Koch"

Claim this Profile
I
Ingestion of mast cell granules boosts macrophages and drives atypical programming.
Konstantinos Katsoulis-Dimitriou, Julia Schmidt, Marc Roder, Jan Dudeck, Lars Philipsen, James P Koch

J Allergy Clin Immunol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Ariella B Hanker, Benjamin P Brown, Jens Meiler, Arnaldo Marín, Harikrishna S Jayanthan, James P Koch

Cancer Cell· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiscale physics of rotating detonation waves: Autosolitons and modulational instabilities.
James Koch, Mitsuru Kurosaka, Carl Knowlen, J Nathan Kutz

Phys Rev E· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Learning dominant physical processes with data-driven balance models.
Jared L Callaham, James V Koch, Bingni W Brunton, J Nathan Kutz, Steven L Brunton

Nat Commun· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteopathic Manipulative Treatment for Inhaled Rib Somatic Dysfunction.
James Koch, Christina Tsui, Joel Talsma, Stacey Pierce-Talsma

J Am Osteopath Assoc· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Dhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, Paula González Ericsson, Alberto Servetto, James Koch

Cancer Cell· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Dhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, Paula González Ericsson, Alberto Servetto, James Koch

Cancer Cell· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mode-locked rotating detonation waves: Experiments and a model equation.
James Koch, Mitsuru Kurosaka, Carl Knowlen, J Nathan Kutz

Phys Rev E· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Encephalopathy induced by Alzheimer brain inoculation in a non-human primate.
Charlotte Gary, Suzanne Lam, Anne-Sophie Hérard, James E Koch, Fanny Petit

Acta Neuropathol Commun· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Ariella B Hanker, Monica Red Brewer, Jonathan H Sheehan, James P Koch, Gregory R Sliwoski

Cancer Discov· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2 Breast Cancer.
Ariella B Hanker, Mónica Valeria Estrada, Giampaolo Bianchini, Preston D Moore, Junfei Zhao, James P Koch

Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
Neil E Bhola, Valerie M Jansen, James P Koch, Hua Li, Luigi Formisano

Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Ariella B Hanker, Joan T Garrett, Mónica Valeria Estrada, Preston D Moore, Paula González Ericsson, James P Koch

Clin Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comparison of the Assay Sensitivity of Average and Worst Pain Intensity in Pharmacologic Trials: An ACTTION Systematic Review and Meta-Analysis.
Shannon M Smith, Mark P Jensen, Hua He, Rachel Kitt, James Koch

J Pain· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Available sight distance on existing highways: Meeting stopping sight distance requirements of an aging population.
Suliman A Gargoum, Mostafa H Tawfeek, Karim El-Basyouny, James C Koch

Accid Anal Prev· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Ariella B Hanker, Joan T Garrett, Mónica Valeria Estrada, Preston D Moore, Paula González Ericsson, James P Koch

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpretation of CIs in clinical trials with non-significant results: systematic review and recommendations.
Jennifer S Gewandter, Michael P McDermott, Rachel A Kitt, Jenna Chaudari, James G Koch

BMJ Open· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Ariella B Hanker, Monica Red Brewer, Jonathan H Sheehan, James P Koch, Gregory R Sliwoski

Cancer Discov· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2 Breast Cancer.
Ariella B Hanker, Mónica Valeria Estrada, Giampaolo Bianchini, Preston D Moore, Junfei Zhao, James P Koch

Cancer Res· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
Neil E Bhola, Valerie M Jansen, James P Koch, Hua Li, Luigi Formisano

Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multifocal radiculoneuropathy during ipilimumab treatment of melanoma.
Georgios Manousakis, James Koch, R Brian Sommerville, Ahmed El-Dokla, Matthew B Harms

Muscle Nerve· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes.
Maroof Hasan, James Koch, Dinesh Rakheja, Asit K Pattnaik, James Brugarolas

Nat Immunol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of tamoxifen on normal human dermal fibroblasts.
Mauro B Ruffy, Shaun S Kunnavatana, R James Koch

Arch Facial Plast Surg· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Growth and growth factor production by human nasal septal chondrocytes in serum-free media.
Magdalena Kita, Matthew M Hanasono, Anthony A Mikulec, Jeffrey D Pollard, James M Kadleck, R James Koch

Am J Rhinol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Facial resurfacing for nonmelanoma skin cancer prophylaxis.
Basil M Hantash, Daniel B Stewart, Zachary A Cooper, Wingfield E Rehmus, R James Koch

Arch Dermatol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis